Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Njdevilsfanon Jul 08, 2017 10:17pm
121 Views
Post# 26448008

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Recent chinese article

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Recent chinese articleI am expecting quick approval. I love this company and think it has a great future. As soon as they get things going with ibalizumab , i would like to see the company diversify, perhaps buy into other companies in other areas. Perhaps they will use the cash they will generate from their two approved drugs to fund an acquisiton or use stock depending on how high the stock price goes. If it goes to $15+, just a few million shares issues could not only give them a nice war chest, but it could buy one or two promising companies.

Additionally, i really hope they look to move to a better US exchange. I believe if the stock was on the Nasdaq, given what's going on and what we expect to happen with their second approval, the stock price would likely do a lot better. The problem is that many people do not follow this one and i wonder if we aren't getting the analyst coverage because of the exchange we are trading on. 
Bullboard Posts